相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。444OPHASE IB TRIAL TRIAL OF RG7116, A GLYCOENGINEERED MONOCLONAL ANTIBODY TARGETING HER3, IN COMBINATION WITH CETUXIMAB OR ERLOTINIB IN PATIENTS WITH ADVANCED/METASTATIC TUMORS OF EPITHELIAL CELL ORIGIN EXPRESSING HER3 PROTEIN
U.N. Lassen et al.
ANNALS OF ONCOLOGY (2017)
Abstract C120: Phase I study of the safety and tolerability of LJM716 in Japanese patients with advanced solid tumors
TAITO ESAKI et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Translating gastric cancer genomics into targeted therapies
Yvonne L. E. Ang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+breast cancer
Debora de Melo Gagliato et al.
ONCOTARGET (2016)
Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer
Makoto Nishio et al.
LUNG CANCER (2015)
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the THERAPY phase 1-2 trial
Eric Assenat et al.
ONCOTARGET (2015)
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
Jeanne Mendell et al.
EBIOMEDICINE (2015)
Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer
Alistair Ring et al.
CLINICAL CANCER RESEARCH (2015)
Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
Kristan Meetze et al.
CLINICAL CANCER RESEARCH (2015)
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
Hiroshi Wakui et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
Douglas A. Rubinson et al.
INVESTIGATIONAL NEW DRUGS (2014)
Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC
Kaihua Zhang et al.
ONCOTARGET (2014)
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
Joan T. Garrett et al.
CANCER RESEARCH (2013)
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Andrew P. Garner et al.
CANCER RESEARCH (2013)
Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Patricia LoRusso et al.
CLINICAL CANCER RESEARCH (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Potential Therapeutic Significance of HER-Family in Esophageal Squamous Cell Carcinoma
Koji Kono et al.
ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY (2012)
Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
Timothy R. Wilson et al.
CANCER CELL (2011)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics
Dhara N. Amin et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2010)
HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract
Noor Al-Dasooqi et al.
CURRENT DRUG TARGETS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Natalia Jura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Carlos L. Arteaga et al.
CLINICAL CANCER RESEARCH (2008)
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
Henry L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Critical aspects of the Bayesian approach to phase I cancer trials
Beat Neuenschwander et al.
STATISTICS IN MEDICINE (2008)
Translation of innovative designs into phase I trials
Andre Rogatko et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
分享论文
